{"filings":[{"id":93486,"accession_number":"0001493152-26-020728","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Processa Pharmaceuticals transitions Chief Development Officer to part-time role effective May 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Sian Bigora moves from full-time executive to part-time employee, retains Chief Development and Regulatory Officer title.","She will no longer be an executive officer under Section 16 of the Exchange Act.","Existing employment agreement terminated; replaced by new part-time arrangement effective May 1, 2026.","Dr. Bigora retains all previously granted equity awards and remains eligible for prior bonus compensation.","Transition is part of her planned path toward retirement, as stated by the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105150,"accession_number":"0001493152-26-007469","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Processa's binding term sheet with Intact Therapeutics for PCS12852 expires without deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Binding Term Sheet dated June 17, 2025 with Intact Therapeutics expired February 12, 2026.","No definitive license agreement was executed regarding PCS12852.","Proposed amendment to the Yuhan Corporation License Agreement was not entered.","Neither party has any remaining obligations under the expired term sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105149,"accession_number":"0001493152-26-000733","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Processa Pharmaceuticals regains compliance with Nasdaq $1.00 minimum bid price; delisting matter closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notification on January 6, 2026 confirming compliance with Listing Rule 5550(a)(2).","Company had previously been notified of bid price deficiency; now the deficiency is resolved.","Nasdaq Capital Market continued listing is no longer at risk from bid price requirement.","No other material changes; CEO George Ng signed the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121403,"accession_number":"0001493152-25-027680","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Processa Pharmaceuticals announces 1-for-25 reverse stock split effective Dec 16, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split reduces outstanding shares 25:1; no change to authorized shares (1B).","Effective 5:00 p.m. ET Dec 16, 2025; split-adjusted trading begins Dec 17, 2025 under symbol PCSA.","New CUSIP number 74275C403; fractional shares rounded up to nearest whole share.","Outstanding options, warrants, and RSUs adjusted proportionally per their terms.","Stockholders' ownership percentages unchanged except for fractional share rounding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138056,"accession_number":"0001493152-25-013648","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K/A","filed_at":"2025-09-16T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Processa shareholders approve 10x authorized share increase and reverse split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved increase in authorized common shares from 100M to 1B (13.7M for, 3.0M against).","Reverse stock split approved with ratio ranging from 1:2 to 1:50, at board's discretion, by Dec 31, 2026.","Amendment to 2019 Omnibus Incentive Plan to increase shares available for issuance approved (13.6M for).","All four proposals passed at special meeting held Sep 11, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138066,"accession_number":"0001493152-25-013108","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Processa shareholders approve 10x increase in authorized shares, reverse split up to 1:50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved increase of authorized common shares from 100M to 1B (13.7M for, 3.0M against).","Approved reverse stock split at ratio 1:2 to 1:50, effective by Dec 31, 2026 (13.9M for).","Approved amendment to 2019 Omnibus Incentive Plan to increase shares available (13.6M for).","Adjournment proposal approved but not needed due to sufficient votes on substantive proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138065,"accession_number":"0001493152-25-012966","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Processa adjourns special meeting; reconvened Sept 11, record date unchanged","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special meeting originally Sept 2 adjourned; now reconvened Sept 11 at 10:30 AM ET in Vero Beach, FL.","Record date remains Aug 7, 2025; previously submitted proxies remain valid.","Proposals unchanged; proxy statement available on SEC website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138064,"accession_number":"0001493152-25-012567","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Processa special meeting adjourned due to lack of quorum; reconvenes Sept 12","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special shareholder meeting on Sept 2, 2025 adjourned without conducting business because a quorum was not present.","Reconvened meeting set for Sept 12, 2025 at 5:00 PM ET in Vero Beach, FL; record date remains Aug 7, 2025.","Shareholders who already voted need not take action; proposals unchanged.","Company will not change record date for the reconvened meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138063,"accession_number":"0001641172-25-025421","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Processa Pharmaceuticals changes 2025 Special Meeting location to Pasadena, CA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board changed 2025 Special Meeting location from Vero Beach, FL to Pasadena, CA (August 25, 2025).","Original location: 601 21st Street, Suite 300, Vero Beach, FL 32960.","New location: 594 East Colorado Blvd., Suite 200, Pasadena, CA 91101."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138055,"accession_number":"0001641172-25-023736","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K/A","filed_at":"2025-08-14T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Processa Pharmaceuticals raises ~$1.3M in private placement; evaluating crypto treasury strategies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$1.3M via private placement of 5.47M restricted shares at $0.23/share.","Engaged LifeSci Capital as financial advisor for capital structure and crypto treasury strategy.","Evaluating corporate cryptocurrency treasury strategies for yield-generation and capital diversification.","Proceeds to be used for general corporate purposes; offering closed August 6, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138062,"accession_number":"0001493152-25-011775","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Processa receives second 180-day grace period to regain Nasdaq bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Grace period runs until February 2, 2026 to meet $1.00 minimum bid price.","Compliance requires closing bid price ≥ $1.00 for 10 consecutive business days.","Company will consider a reverse stock split if needed to cure deficiency.","Common stock continues trading on Nasdaq Capital Market during the period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138061,"accession_number":"0001493152-25-011680","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Processa raises $1.3M in private placement; evaluating crypto treasury strategy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 5,467,181 restricted shares at $0.23/share for ~$1.3M gross proceeds.","Placement agent LifeSci Capital receives 7% cash fee; offering closed August 6, 2025.","Net proceeds for general corporate purposes; company evaluating corporate cryptocurrency treasury strategies.","Crypto strategy aims to diversify capital base, reduce dilution, and fund clinical programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138060,"accession_number":"0001493152-25-011419","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Processa Pharmaceuticals files prospectus supplement to sell up to $5.2 million shares of common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On July 25, 2025, Processa filed a prospectus supplement to its Form S-3 (Registration No. 333-279588) for an equity distribution agreement with A.G.P./Alliance Global Partners.","The supplement permits the sale of $5,239,073 shares of common stock, with $1,546,338 shares already sold in the prior 12 months.","As of the prospectus supplement date, $3,692,735 shares remain available for sale under the agreement.","The offering is conducted via an at-the-market equity distribution agreement with A.G.P./Alliance Global Partners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138059,"accession_number":"0001493152-25-011305","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Processa shareholders elect all six directors and approve warrant share issuance at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected: Justin Yorke, George Ng, Khoso Baluch, James Neal, Geraldine Pannu, Dr. David Young.","Proposal to issue shares upon exercise of Series A and B warrants approved with 1,646,114 for, 275,707 against, 24,613 abstain.","Ratification of Cherry Bekaert, LLP as independent auditor for FY2025 passed with 3,752,298 for, 166,735 against.","Advisory vote on executive compensation approved: 1,704,544 for, 224,727 against, 17,163 abstain.","Meeting held July 18, 2025; broker non-votes on director and other proposals totaled 2,035,053 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138058,"accession_number":"0001641172-25-019663","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Processa Pharmaceuticals adjourns annual meeting due to lack of quorum; reconvened on July 18, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting on June 30, 2025, adjourned due to insufficient quorum; no business conducted.","Meeting reconvened on July 18, 2025, at 9:00 AM in Hanover, MD; record date unchanged (May 1, 2025).","Proxies already submitted remain valid; no action needed for shareholders who have already voted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138057,"accession_number":"0001641172-25-017288","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Processa Pharmaceuticals Announces Strategic Portfolio Review, Pipeline Realignment, and $7M Capital Infusion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated licensing agreement with Ocuphire Pharma (now Opus Genetics) for PCS3117, returning rights to original licensor.","Signed binding term sheet with Intact Therapeutics granting exclusive option to license PCS12852; eligible for up to $454M milestones and 12% royalty.","Continues enrolling patients in Phase 2 study of PCS6422 (NGC-Cap) for metastatic breast cancer; interim data expected H2 2025.","Strengthened balance sheet with $7 million capital infusion.","Establishing dedicated subsidiary for PCS499; designing new adaptive pivotal Phase III study for rare kidney disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155467,"accession_number":"0001641172-25-017185","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["1.01","5.07","9.01"],"status":"ready","headline":"Processa amends Yuhan license; annual meeting adjourned for lack of quorum","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Amendment No. 1 to License Agreement with Yuhan Corporation effective June 11, 2025, linked to term sheet with Intact Therapeutics dated June 17, 2025.","Annual meeting on June 30, 2025 adjourned due to insufficient quorum; reconvened for July 30, 2025 at 1:00 PM in Hanover, MD.","Record date remains May 1, 2025; previously submitted proxies and votes remain valid without further action.","No financial or operational details of the Yuhan amendment or Intact Therapeutics term sheet were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155466,"accession_number":"0001641172-25-015654","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Processa prices $7M public offering of common stock and warrants at $0.25/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $7M before expenses; offering of 28M shares/pre-funded warrants plus 28M common warrants.","Combined price $0.25 per share (or pre-funded warrant) and accompanying common warrant.","Common warrants exercisable at $0.25/share for 5 years, immediately exercisable.","Net proceeds to fund Phase 2 trial of NGC-Cap and for working capital & general corporate purposes.","H.C. Wainwright acted as placement agent; receives 7% cash fee and 1.12M Placement Agent Warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155465,"accession_number":"0001641172-25-015355","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Processa grants Intact exclusive option to license PCS12852 for up to $452.5M milestones plus royalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Near-term payments: $2.5M option exercise fee plus 3.5% equity stake in Intact upon closing.","Up to $20M in development/regulatory milestones and over $432.5M in commercial milestones on net sales.","Double-digit royalty on worldwide net sales (ex-South Korea); Processa must share 60% of cash payments with licensor Yuhan.","PCS12852 is a Phase 2-ready 5-HT4 agonist for diabetic gastroparesis with positive Phase 2a safety/efficacy data.","Definitive license agreement subject to 120-day diligence, extension for $30K, and Yuhan amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173960,"accession_number":"0001493152-25-005830","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Processa Pharmaceuticals posts investor presentation; details not available in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Regulation FD disclosure of a slide presentation dated February 2025.","Presentation intended for publication on the company website.","No specific financial, clinical, or operational metrics provided in the filing text.","Exhibit 99.1 (slides) not included in the submitted materials; content unknown."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173959,"accession_number":"0001493152-25-005633","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Processa receives Nasdaq bid-price deficiency notice; 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Processa that common stock bid price closed below $1.00 for 30 consecutive business days.","Company has until August 4, 2025 to regain compliance by closing at $1.00 or more for 10 consecutive days.","If not compliant by deadline, may qualify for a second 180-day period or face potential delisting.","Stock continues trading under symbol PCSA on Nasdaq Capital Market during cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173958,"accession_number":"0001493152-25-004298","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Processa closes $5M public offering; Series A/B warrants at $0.65 exercise price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $5.0M from offering closed Jan 29, 2025; net proceeds for general corporate purposes.","Offered 8,050,672 shares (or pre-funded warrants) at combined price of $0.615 (institutions) / $0.7975 (CEO/board) with Series A and B warrants.","Series A warrants exercisable at $0.65 for 5 years, Series B at $0.65 for 18 months, both subject to stockholder approval.","CEO and certain board members participated alongside a healthcare-focused institutional investor; A.G.P. acted as sole placement agent.","Company to seek stockholder approval within 90 days for warrant share issuance; otherwise will call meetings every 90 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190932,"accession_number":"0001493152-24-043821","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Processa Pharmaceuticals replaces auditor BD & Co. with Cherry Bekaert","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BD & Co. resigned Oct 31, 2024 after merger into Citrin Cooperman; no disagreements or reportable events.","Audit Committee appointed Cherry Bekaert LLP for FY 2024 and subsequent interim periods.","No prior consultations with Cherry Bekaert regarding accounting principles or disagreements.","BD & Co.'s audit reports for 2023 and 2022 were unqualified and contained no adverse opinion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190931,"accession_number":"0001493152-24-039220","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Processa Pharmaceuticals doses first patient in Phase 2 trial of NGC-Cap for metastatic breast cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 2 trial (NCT06568692) of NGC-Cap vs capecitabine in 60-90 advanced/metastatic breast cancer patients.","Phase 2 trial satisfies diligence milestone under license agreement with Elion Oncology for PCS6422; Condition Precedent date corrected to Oct 6, 2024.","Three clinical sites with IRB approval activated; plans for ~30 sites worldwide.","Interim analysis results from Phase 2 trial expected mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207419,"accession_number":"0001493152-24-034115","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Processa provides pipeline update, Q2 net loss $3.0M; Phase 2 NGC-Cap trial underway","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA cleared IND for NGC-Cap Phase 2 in July 2024; multicenter trial in metastatic breast cancer initiated, initial data expected mid-2025.","Net loss for Q2 2024 was $3.0M ($1.01 per share) vs $2.6M ($1.94 per share) in Q2 2023; per-share reflects 1-for-20 reverse split.","Cash and cash equivalents $5.6M as of June 30, 2024; R&D expenses unchanged at $1.7M, G&A increased to $1.4M.","Preclinical NGC-Iri study shows greater SN-38 accumulation in tumor vs non-cancer tissues compared to irinotecan and Onivyde.","NGC-Cap Phase 1b data: 66.7% of patients had partial response or stable disease; progression-free survival 5-11 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207418,"accession_number":"0001493152-24-029514","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA clears IND for Processa's NGC-Cap Phase 2 trial in breast cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for NGC-Cap Phase 2 trial in advanced/metastatic breast cancer.","Phase 2 trial enrollment expected to begin in Q3 2024.","Initial data from the Phase 2 trial expected mid-2025.","Phase 1b showed NGC-Cap provides 5-10x more 5-FU exposure and better safety than capecitabine alone.","Trial is global, open-label, adaptive design with 60-90 patients; compares two doses of NGC-Cap to capecitabine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207417,"accession_number":"0001493152-24-028093","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Processa appoints Russell Skibsted as CFO; James Stanker retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Russell Skibsted appointed CFO effective July 16, 2024; succeeds James Stanker who retired.","Skibsted brings 30 years of pharma finance experience; most recently CFO of Alimera Sciences.","Annual base salary $400,000; eligible for 35% target bonus and 28,000 RSUs upon goal achievement.","Stanker remains part-time employee during transition period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207416,"accession_number":"0001493152-24-025884","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Processa shareholders elect directors, approve equity plan increase and auditor ratification","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees (Yorke, Ng, Baluch, Neal, Pannu, Young) elected with over 878K 'For' votes each.","Amendment to 2019 Omnibus Incentive Plan increasing share pool by 500,000 shares approved (779,164 for, 176,802 against).","Ratification of BD & Company as independent auditor for 2024 passed with 1,490,908 for, 32,346 against.","Advisory vote on executive compensation approved with 804,087 for, 164,034 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224834,"accession_number":"0001493152-24-020883","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Processa enters ATM equity agreement to sell up to $2.4M in common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales agreement with A.G.P./Alliance Global Partners for at-the-market offering of up to $2.4 million.","Sales Agent receives up to 3% commission on gross proceeds from shares sold.","Net proceeds to fund R&D for oncology drug candidates and working capital.","Registration statement filed on May 21, 2024 but not yet effective.","Company is not obligated to sell any shares under the agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224833,"accession_number":"0001493152-24-014278","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Processa presents NGC-Cap Phase 1b data at AACR; poster modified","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["David Young, President R&D, presented two abstracts at AACR 2024 on NGC-Cap and Project Optimus.","NGC-Cap Phase 1b data shows significantly increased 5-FU exposure and improved safety vs capecitabine.","The originally presented poster was subsequently modified; amended posters posted on company website.","Second abstract addresses optimal dose using Phase 1 and preclinical data under Project Optimus.","No specific numerical results disclosed in filing; detailed data available in website publications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224832,"accession_number":"0001493152-24-013132","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Processa CEO presents at MedInvest conference; no specific material data in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO George Ng presented at MedInvest Biotech + Pharma Investor Conference on April 3, 2024 in NYC.","Presentation titled 'Next Generation Chemotherapy: Improved Treatment for More Patients' was at 10:55 AM ET.","President R&D David Young attended the meeting virtually.","Presentation furnished as Exhibit 99.1 but not included in this filing; no numbers or clinical data disclosed.","Company directs investors to website for presentation and routine disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244108,"accession_number":"0001493152-24-007444","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CEO George Ng presents at Winter Wrap-Up MicroCap Rodeo Conference, Feb 20, 2024","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation furnished as Exhibit 99.1; no financial results or guidance provided.","Presentation available on Processa's website under Investors section.","Filing contains no material new information beyond the conference presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244107,"accession_number":"0001493152-24-005029","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2024-02-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Processa regains Nasdaq minimum bid price compliance; delisting risk resolved","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received written notice from Nasdaq on Feb 6, 2024 confirming compliance with Listing Rule 5550(a)(2).","Achieved minimum $1.00 closing bid price for 10 consecutive business days ending Feb 2, 2024.","Matter is now closed; no further deficiency or delisting action pending.","Stock ticker PCSA; compliance removal removes immediate delisting overhang."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244106,"accession_number":"0001493152-24-004251","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Processa Pharmaceuticals prices $7M public offering of 1.56M shares and warrants at $4.50 per unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing of 1,555,555 shares (or pre-funded warrants) and common warrants at $4.50 per unit; gross proceeds ~$7M.","Common warrants exercisable at $4.50/share, immediately exercisable, 5-year term; pre-funded warrants at $0.0001.","H.C. Wainwright & Co. as sole placement agent with 7.0% cash fee and placement agent warrants.","Offering closed Jan 30, 2024; net proceeds for general corporate purposes.","90-day lock-up on equity issuance subject to exceptions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244105,"accession_number":"0001493152-24-003705","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Processa completes Phase 1b of NGC-Cap; recommends two Phase 2 doses for advanced breast cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1b trial in 18 advanced GI cancer patients achieved 2-10x greater 5-FU exposure than FDA-approved capecitabine.","Hand-foot-syndrome incidence only 6% (1 of 16) vs >50% for capecitabine; severe HFS 0% vs >10%.","Myelosuppression at lower 150 mg BID dose: 33% overall, 0% severe vs 80% and 3% for capecitabine.","Of 5 evaluable patients at highest doses, 80% had positive response (1 partial response, 3 stable disease).","Phase 2 will target advanced/metastatic breast cancer using two selected dosing regimens."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244104,"accession_number":"0001493152-24-002983","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Processa expands NGC-Cap into breast cancer; FDA agrees existing data supports Phase 2 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA agreed existing data can directly support Phase 2 breast cancer trial design.","Plan to initiate Phase 2 study in advanced/metastatic breast cancer in Q3 2024.","Breast cancer represents larger market than colorectal; potential for >250,000 patients/year.","Company identified breast cancer KOLs for scientific advisory board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244103,"accession_number":"0001493152-24-002835","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2024-01-18T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Processa Pharmaceuticals to effect 1-for-20 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1-for-20, effective 12:01 a.m. ET Jan. 22, 2024.","Outstanding shares reduce from ~24.6M to ~1.2M.","No fractional shares; rounding up to nearest whole share.","Intended to regain compliance with Nasdaq $1 minimum bid price.","Stock continues trading under symbol PCSA with new CUSIP 74275C304."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244102,"accession_number":"0001493152-24-001713","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Processa CEO presents at Biotech Showcase 2024; no financial updates provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO George Ng presentation on Jan 8, 2024 at 1:00 PM PT in San Francisco.","Presentation titled 'Next Generation Chemotherapy: Improved Treatment for More Patients'.","Presentation uploaded to investor portal and available on company website.","No specific financial or pipeline results disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261519,"accession_number":"0001493152-23-045362","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2023-12-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Processa Pharma: Phase 1b interim data show NGC-Cap improved safety with 10x higher 5-FU exposure than capecitabine","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NGC-Cap doses: 75-225 mg twice daily vs capecitabine's 1600-2500 mg twice daily; 5-FU exposure up to 10x greater.","Anabolite side effect profile similar to capecitabine; FBAL-related side effects (hand-foot syndrome) almost absent; FBAL exposure ~1% of capecitabine.","FDA acknowledges NGC-Cap as a New Chemical Entity based on altered metabolism and distribution of 5-FU.","Fireside chat scheduled Dec 20 at 4:30 PM ET to discuss data and corporate strategy; results require further studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261518,"accession_number":"0001493152-23-043743","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2023-12-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Processa Pharmaceuticals presents at MedInvest Oncology Conference on Dec 5, 2023","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dr. David Young, President R&D, presents virtually at MedInvest Oncology Conference on Dec 5, 2023.","Presentation titled 'Next Generation Chemotherapy: Improved Treatment for More Patients' at 1:35 PM PT/4:35 PM ET.","CEO George Ng attends in person and is available for Q&A and one-on-one meetings.","Presentation uploaded to investor portal and made available on Processa's website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261517,"accession_number":"0001493152-23-041652","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Processa Pharmaceuticals presents at Orphan Drugs Congress; no material new data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Dr. David Young, President of R&D, presented on Nov 16, 2023 at 2:40 PM ET at the 20th Orphan Drugs and Rare Diseases Global Congress in Boston.","Presentation title: 'Benefit-Risk Analysis for FDA Approval Requires More Than a Pivotal Trial'.","Presentation furnished as Exhibit 99.1 but exhibit text not provided; no specific numbers, milestones, or guidance detailed in the 8-K.","Company undertakes no obligation to update this Reg FD disclosure; no changes to business or financial condition reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261516,"accession_number":"0001493152-23-041422","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Processa Pharma shareholders approve reverse stock split at ratio up to 1:30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved reverse stock split at ratio between 1:5 and 1:30, board to set exact ratio.","Votes: 13,895,377 for, 1,341,351 against, 21,455 abstain; 62% quorum of outstanding shares.","Reverse split must be executed by March 18, 2024, at board's discretion.","Adjournment proposal also approved but not needed since main proposal passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261515,"accession_number":"0001493152-23-040439","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Processa Pharmaceuticals board member Virgil Thompson passes away at 83","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Virgil Thompson, age 83, died unexpectedly on November 9, 2023.","He served on the Board since 2017 and chaired the Nominating and Governance Committee.","The company has no immediate plans to appoint a new board member."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261514,"accession_number":"0001493152-23-037299","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2023-10-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Processa Pharmaceuticals furnishes October 2023 investor presentation; content not provided in filing excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Slide presentation published to company website as of Oct. 16, 2023.","Presentation speaks as of the filing date; company disclaims obligation to update.","No specific financial or clinical data from the presentation available in this extract."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278733,"accession_number":"0001493152-23-033372","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2023-09-21T23:59:59+00:00","items":["3.01","5.03","9.01"],"status":"ready","headline":"Nasdaq grants Processa second 180-day grace period to meet $1.00 bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Sept 19; second compliance period ends March 18, 2024.","Must maintain closing bid price ≥$1 for 10 consecutive days to regain compliance.","Board adopted amended bylaws including majority voting on routine matters and exclusive Delaware forum for derivative suits.","Directors now removable only for cause by 66% stockholder vote; board can change director count without stockholder vote.","Company may pursue reverse stock split to cure deficiency if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278732,"accession_number":"0001493152-23-029250","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2023-08-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Processa presents at Sidoti conference; no material financial data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company presented on August 17, 2023, at the Sidoti Micro-Cap Virtual Conference.","David Young, Pharm.D., Ph.D., presented the corporate update during Track 2 at 11:30 AM ET.","Presentation is available on Processa's website under the Investors section.","No specific clinical trial results, financial guidance, or pipeline changes were detailed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278731,"accession_number":"0001493152-23-027122","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Processa Pharmaceuticals appoints George Ng as CEO; COO Floyd to resign Aug 31","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["George Ng appointed CEO and director effective Aug 8, 2023; previously president/COO of Calidi Biotherapeutics.","David Young steps down as CEO but remains President of R&D and board member; focuses on NGC drugs.","R. Michael Floyd resigns as COO by mutual agreement, effective August 31, 2023.","Ng receives $400k base salary, up to $100k bonus, and 800k RSUs (400k time-vest, 400k performance-based).","Ng previously led Scilex through $140M financing, FDA approval, and sale; holds JD from Notre Dame."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296972,"accession_number":"0001493152-23-022920","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Processa increases authorized common shares to 100M; all director nominees elected at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to increase authorized common stock from 50M to 100M shares.","All six director nominees (Yorke, Young, Baluch, Neal, Pannu, Thompson) elected with >9.8M votes each.","Ratification of BD & Company as independent auditor for FY 2023 approved with 12.86M for.","Advisory vote on executive compensation passed with 9.72M for, 1.92M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296971,"accession_number":"0001493152-23-021934","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Processa CEO presents at MedInvest Oncology Investor Conference","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Dr. David Young presented on June 21, 2023 at 12:00 PM ET in Boston.","Presentation titled 'Next Generation Chemotherapy to Improve Treatment of Cancer while Treating More Patients'.","No specific financial or pipeline data disclosed; presentation posted on Processa's investor website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296970,"accession_number":"0001493152-23-018883","cik":1533743,"company_name":"Processa Pharmaceuticals, Inc.","ticker":"PCSA","form_type":"8-K","filed_at":"2023-05-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Processa Pharma presents at World Orphan Drug Congress on Project Optimus for rare cancers","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Dr. David Young participates in panel titled 'Clinical Development & Regulatory Panel Session: Patient focused drug development' at World Orphan Drug Congress on May 24, 2023.","Also presents Pitch and Partner presentation titled 'Applying FDA’s Project Optimus to the Next Generation of Chemotherapy Drugs Treating Rare Cancers' at 1:00 PM ET.","Presentation made available in Investors section of company website; detailed content not disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7246706.439330543,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-05-24T23:59:59+00:00|296970"}